close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kazia Therapeutics Limited - American Depositary Shares (NQ:KZIA)

6.870 -1.170 (-14.55%)
Delayed Quote Updated: 3:05 PM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kazia Therapeutics Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
The Daily Biotech Pulse: Addex Terminates Parkinson's Study, Expanded Use Of Rhythm's Obesity Drug, FDA Approval For AbbVie's Skyrizi In Crohn's Disease ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Kazia Therapeutics' Shares Gain Following FDA Orphan Drug Status For Childhood Brain Cancer Drug ↗
The United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Kazia Therapeutics’ (NASDAQ: KZIA) Paxalisib for the treatment of atypical rhabdoid / teratoid tumors... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Kazia Therapeutics (KZIA): Deep Dive Into Childhood Brain Cancer
LONDON, UK / ACCESSWIRE / May 26, 2022 / In light of the positive newsflow from Kazia's efforts in addressing adult brain cancer, management is leveraging its niche expertise and experience to address... 
From Edison Investment Research Limited
Via AccessWire
News headline image
Kazia Therapeutics Concludes Mid-Stage Paxalisib Study In Brain Cancer ↗
Kazia Therapeutics Limited (NASDAQ: KZIA) has completed a Phase 2 study of paxalisib in glioblastoma. 
Via Benzinga
News headline image
The Daily Biotech Pulse: Ampio Falls On Knee Osteoarthritis Trial Update, AstraZeneca's COVID-19 Antibody Data, CureVac-GSK's Bivalent COVID-19 Vaccine Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Kazia TherapeuticsTrust (KZIA): Several Upcoming Catalysts
LONDON, UK / ACCESSWIRE / March 30, 2022 / Patient recruitment in the pivotal GBM AGILE study for lead asset paxalisib remains on track, with data expected in CY23, to be followed by a potential... 
From Edison Investment Research Limited
Via AccessWire
News headline image
A Peek Into The Markets: US Stock Futures Gain After S&P 500 Hits Record High ↗
Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones surged more than 200 points in the previous session. Investors are awaiting earnings... 
Via Benzinga
Topics Stocks
News headline image
60 Biggest Movers From Yesterday ↗
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 200.4% to close at $15.05 on Monday after the company announced the commencement of a formal process to explore... 
Via Benzinga
News headline image
Kazia Unveils Final Data From Mid-Stage Paxalisib Data In Newly Diagnosed Glioblastoma Patients ↗
Australia-based Kazia Therapeutics Limited (NASDAQ: KZIA) announced final data from a Phase 2 study of paxalisib as first-line therapy in patients with... 
Via Benzinga
News headline image
A Peek Into The Markets: US Stock Futures Higher Ahead Of Tyson Foods Earnings ↗
Pre-open movers U.S. stock futures traded higher in early pre-market trade after closing higher in the prior session. Investors are awaiting earnings results from Tyson Foods,... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021 ↗
Upgrades According to Roth Capital, the prior rating for Ring Energy Inc (AMEX: 
Via Benzinga
News headline image
Kazia TherapeuticsTrust (KZIA): Multiple Paxalisib Data Points Expected in Q4
LONDON, UK / ACCESSWIRE / October 14, 2021 / Kazia expects to release multiple data points from its paxalisib program in Q4 CY21. These include final data from the 30-patient Phase II trial in newly... 
From Edison Investment Research Limited
Via AccessWire
News headline image
Kazia Therapeutics (KZIA): New asset to target tumor lymphangiogenesis
LONDON, UK / ACCESSWIRE / April 20, 2021 / Kazia announced that it is expanding its pipeline to include EVT801, a novel small molecule inhibitor of VEGFR3. The drug is being licensed from Evotec for... 
From Edison Investment Research Limited
Via AccessWire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Akumin (NASDAQ:AKU) shares increased by 13.54% to $3.52 during Wednesday's pre-market session. The market value of their outstanding shares is at $247.0... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.